Many have been following San Diego-based Dexcom’s partnership with Alphabet’s Verily, and in November the continuous glucose monitoring maker announced that it has changed the financial terms of the ...
DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE ...
Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship G7 sensor. The new system, which boosts wear time up from the previous ...
The FDA is aware that Dexcom has sent all affected customers an Urgent Medical Device Correction Notification for the Dexcom G7 Continuous Glucose Monitoring (CGM) App (for Android, iOS, and watchOS ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 15-day Dexcom G7 had a MARD of 8%, a small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback